Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

Inclusion Criteria: 1. Age between 18 and 80 years old, and expected survival is longer than 3 months 2. Clinically or pathologically diagnosed as primary hepatocellular carcinoma 3. Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment 4. Child-Pugh score of liver function A/B (\< 7) 5. At least one lesion is suitable for mRECIST assessment 6. Strength score (ECOG): 0-1 7. The patient and/or family members agree to join the clinical trial and sign the informed consent form Exclusion Criteria: 1. Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon 2. Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation 3. Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10\^4 before receiving treatment or do not continue to take antiviral drugs regularly 4. Pregnant patients 5. Combined with other malignant tumors, or have a history of other malignant tumors within 3 years 6. Active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication 7. Severe renal dysfunction: creatinine (Cr) \> 2 mg/dL or creatinine clearance (CCr) \<30 mL/min, severe heart, lung, brain and other important organ diseases 8. History of gastrointestinal bleeding within 3 months 9. Unable to cooperate with ablation surgery 10. Severe gastroesophageal varices